unfractioned heparin

Phase 3Small molecule

unfractioned heparin is one of 134 small molecule programs targeting Acute Myocardial Infarction. It is currently in Phase 3.

Indications

Total Trials

Active Trials

133

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myocardial InfarctionActive, not recruiting

NecrosisActive, not recruiting

SepsisActive, not recruiting

Myocardial InfarctionActive, not recruiting

Acute Myocardial InfarctionPhase 3

Active, not recruiting

NecrosisPhase 3

Active, not recruiting

SepsisPhase 3

Active, not recruiting

Myocardial InfarctionPreclinical

Active, not recruiting

Competition

Competitive Landscape

308 competitors in Sepsis

#DrugCompanyPhaseTrials

unfractioned heparin

Boehringer Ingelheim

Phase 3

1 2

Corlanor

Amgen

Preclinical

2 3

Zyvox

Primaxin

Brevibloc

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

3 6

Levophed

GGeneral Hospital of Ningxia Medical University

Preclinical

2 7

Micardis

Boehringer Ingelheim

Preclinical

1 8

Jardiance

Boehringer Ingelheim

Preclinical

1 9

Levaquin

WWim Janssens

Preclinical

1 10

Achromycin V

WWyeth-Lederle Vaccines

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hemodialysis1 trial

OPG and RANKL Plasma Level After Administration of Unfractionated Heparin (UFH) and Low-Molecular-Weight Heparin (LMWH) in Hemodialysis

Unknown status·IIRCCS Azienda Ospedaliero-Universitaria di Bologna·N/A·NCT00669721·40 enrolled

Necrosis1 trial

Bivalirudin Plus Stenting in Long Lesion to Avoid Periprocedural Myocardial Necrosis Trial

Unknown status·UUniversity of Roma La Sapienza·Phase 3·NCT01555658·204 enrolled

Sepsis1 trial

Unfractioned Heparin for Treatment of Sepsis

Completed·UUniversidad de Antioquia·Phase 3·NCT00100308·319 enrolled

Acute Myocardial Infarction1 trial

A Trial on Efficacy and Safety of Full Dose Tenecteplase Combined With Unfractionated Heparin (UFH) or Enoxaparin in Acute Myocardial Infarction (AMI) in the Prehospital Setting

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02181998·1,606 enrolled

Myocardial Infarction1 trial

Platelet Inhibition After Pre-hospital Ticagrelor Using Fentanyl Compared to Morphine in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Completed·—·N/A·NCT02531165·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for unfractioned heparin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — unfractioned heparin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for unfractioned heparin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Boehringer Ingelheim

unfractioned heparin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hemodialysis1 trial

Necrosis1 trial

Sepsis1 trial

Acute Myocardial Infarction1 trial

Myocardial Infarction1 trial

References

Drug Info

Quick Facts

Related News